[
    [
        {
            "time": "2019-04-26",
            "original_text": "复星医药：一季度净利润同比增长0.92%",
            "features": {
                "keywords": [
                    "复星医药",
                    "一季度",
                    "净利润",
                    "同比增长"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药：一季度净利润同比增长0.92%",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-04-26",
            "original_text": "复星医药(02196-HK)首季多赚近1%",
            "features": {
                "keywords": [
                    "复星医药",
                    "首季",
                    "盈利增长"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药(02196-HK)首季多赚近1%",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-04-26",
            "original_text": "复星医药(02196.HK)一季度归母净利润增长0.92%至7.12亿元",
            "features": {
                "keywords": [
                    "复星医药",
                    "一季度",
                    "归母净利润",
                    "增长"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药(02196.HK)一季度归母净利润增长0.92%至7.12亿元",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        },
        {
            "time": "2019-04-26",
            "original_text": "复星医药(02196.HK)注册资本将减少至25.63亿元",
            "features": {
                "keywords": [
                    "复星医药",
                    "注册资本",
                    "减少"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "复星医药(02196.HK)注册资本将减少至25.63亿元",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-04-26",
            "original_text": "医疗保健：带量采购执行情况超预期 荐9股",
            "features": {
                "keywords": [
                    "医疗保健",
                    "带量采购",
                    "执行情况",
                    "超预期"
                ],
                "sentiment_score": 0.85,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医疗保健：带量采购执行情况超预期 荐9股",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-04-26",
            "original_text": "后“年报季”聚焦高景气领域，关注业绩增长可持续性｜【光大医药·周报】",
            "features": {
                "keywords": [
                    "年报季",
                    "高景气领域",
                    "业绩增长",
                    "可持续性"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "后“年报季”聚焦高景气领域，关注业绩增长可持续性｜【光大医药·周报】",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-04-26",
            "original_text": "上证50指数涨超1%",
            "features": {
                "keywords": [
                    "上证50指数",
                    "涨超1%"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "上证50指数涨超1%",
                "Correlation": 2,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 1,
                "Market_Scope": 10,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-04-26",
            "original_text": "【医药-复星医药(600196)】江琦、赵磊：公司点评：创新研发平台接连发力，报产国内首个曲妥珠单抗生物类似药",
            "features": {
                "keywords": [
                    "复星医药",
                    "创新研发",
                    "曲妥珠单抗",
                    "生物类似药"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【医药-复星医药(600196)】江琦、赵磊：公司点评：创新研发平台接连发力，报产国内首个曲妥珠单抗生物类似药",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-04-27",
            "original_text": "【山证医药】医药行业周报（20190427）：市场大幅调整，关注有基本面支撑的优质个股",
            "features": {
                "keywords": [
                    "医药行业",
                    "周报",
                    "市场调整",
                    "基本面支撑",
                    "优质个股"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "【山证医药】医药行业周报（20190427）：市场大幅调整，关注有基本面支撑的优质个股",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        }
    ]
]